A

Algernon Pharmaceuticals Inc
CNSX:AGN

Watchlist Manager
Algernon Pharmaceuticals Inc
CNSX:AGN
Watchlist
Price: 0.05 CAD -9.09% Market Closed
Market Cap: CA$1.7m

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
CA$0
/
CA$0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
CA$0
/
CA$0

Peer Comparison

Country Company Market Cap Operating
Margin
CA
Algernon Pharmaceuticals Inc
CNSX:AGN
1.7m CAD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
236.4B USD
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
187.8B USD
Loading...
US
Abbott Laboratories
NYSE:ABT
186.8B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
137.1B USD
Loading...
IE
Medtronic PLC
NYSE:MDT
129.3B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
48.4B EUR
Loading...
US
Edwards Lifesciences Corp
NYSE:EW
48.6B USD
Loading...
US
Resmed Inc
NYSE:RMD
36.8B USD
Loading...
CN
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
235.6B CNY
Loading...
JP
Fujifilm Holdings Corp
TSE:4901
3.8T JPY
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Algernon Pharmaceuticals Inc
Glance View

Market Cap
1.7m CAD
Industry
N/A

Algernon Pharmaceuticals Inc is a CA-based company operating in industry. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2016-02-01. Algernon Pharmaceuticals Inc. is a clinical stage pharmaceutical development company that is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough. The Company’s drug discovery approach is based on the concept of drug repurposing. Drug repurposing is the process of discovering new therapeutic uses for existing drugs. Its research and development (R&D) work are carried out by the Company’s Canadian subsidiary, Nash Pharmaceuticals Inc. (Nash Pharma). The Company’s lead compound is a drug called Ifenprodil, which is being developed for idiopathic pulmonary fibrosis (IPF) and chronic cough, as well as coronavirus disease of 2019 (COVID-19).

AGN Intrinsic Value
0.02 CAD
Overvaluation 59%
Intrinsic Value
Price
A
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top